Oleg Gluz, MD

Conference Coverage

Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer

11/10/2023

Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.

Oleg Gluz, MD, Evangelical...

11/10/2023

Oncology

Videos

Response to Short Preoperative Endocrine Therapy Among Patients With HR-Positive, HER2-Negative Breast Cancer

12/08/2023

Oleg Gluz , MD;

Oleg Gluz, MD, shares results from the screening cohort of the phase 3 ADAPTcycle trial.

Oleg Gluz, MD, shares results...

12/08/2023

Oncology

Videos

Neoadjuvant Endocrine Therapy vs De-Escalated Chemotherapy for HR-Positive, HER2-Positive Early Breast Cancer

09/15/2024

Oleg Gluz , MD;

Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...

Oleg Gluz, MD, discusses results...

09/15/2024

Oncology